NCT04689204

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

A Study of CTA30X Cell Injection in the Treatment of Relapsed or Refractory CD19-positive B-line Hematological Malignancies

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: He Huang · Academic / Other
• Sex: All
• Age: 3 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A study of CTA30X cell injection in the treatment of relapsed or refractory CD19-positive B-line hematological malignancies

Detailed description

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-line hematological malignancy: B-ALL and B-NHL. the selection of dose levels and the number of subjects are based on clinical tiral of similar foreign products. 3 groups of patients will be enrolled, 36 in each group. Primary objective is to explore the safety, main consideration is dose-related safety.

Conditions

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	CTA30X	CTA30X cell injection by intravenous infusion

Timeline

• Start date: 2020-12-29
• Primary completion: 2022-12-29
• Completion: 2024-05-31
• First posted: 2020-12-30
• Last updated: 2025-01-24

Locations

1 site across 1 country: China